文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

代谢手术与2型糖尿病合并肥胖患者主要不良心血管结局的关联

Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity.
PubMed 文献 · JAMA · 2019-01-01
一句话结论在2型糖尿病合并肥胖患者中,代谢手术相比非手术管理可显著降低主要不良心血管事件风险(校正HR 0.61,95%CI 0.55-0.69)。

本研究为回顾性队列研究,纳入美国克利夫兰诊所医疗系统1998至2017年间287438例成人糖尿病患者,其中2287例接受代谢手术,按1:5匹配非手术的糖尿病合并肥胖患者(BMI≥30),最终纳入13722例。主要终点为扩展主要不良心血管事件(包括全因死亡、冠状动脉事件、脑血管事件、心力衰竭、肾病和心房颤动)。结果显示,代谢手术组8年累积发生率为30.8%,非手术组为47.7%(P<.001),绝对风险差16.9%(95%CI 13.1%-20.4%),校正HR 0.61(95%CI 0.55-0.69)。全因死亡也显著降低(校正HR 0.59,95%CI 0.48-0.72)。结论认为,代谢手术与主要不良心血管事件风险降低相关,但需随机临床试验证实。

要点

  • 在2型糖尿病合并肥胖(BMI≥30)患者中,代谢手术组8年主要不良心血管事件累积发生率为30.8%,非手术组为47.7%(P<.001)。
  • 代谢手术与主要不良心血管事件风险降低独立相关(校正HR 0.61,95%CI 0.55-0.69;绝对8年风险差16.9%,95%CI 13.1%-20.4%)。
  • 全因死亡率在代谢手术组为10.0%(8年累积),非手术组为17.8%(校正HR 0.59,95%CI 0.48-0.72)。
  • 所有7个预设次要终点均显示代谢手术组有统计学显著获益。
  • 该研究为观察性研究,作者指出结果需在随机临床试验中证实。

适用人群与场景

  • 美国克利夫兰诊所医疗系统1998至2017年间287438例成人糖尿病患者中,接受代谢手术的2287例,以及按1:5匹配的非手术糖尿病合并肥胖(BMI≥30)患者11435例。
  • 随访至2018年12月。

研究设计与关键结果

  • 研究类型:回顾性队列研究,共纳入13722例受试者(代谢手术组2287例,非手术对照组11435例),来自美国克利夫兰诊所医疗系统。
  • 基线特征:女性比例手术组65.5% vs 非手术组64.2%;中位年龄52.5 vs 54.8岁;BMI 45.1 vs 42.6;糖化血红蛋白7.1% vs 7.1%。
  • 主要终点(扩展MACE复合终点):代谢手术组385例发生事件,非手术组3243例;8年累积发生率30.8%(95%CI 27.6%-34.0%) vs 47.7%(95%CI 46.1%-49.2%),P<.001;绝对8年风险差16.9%(95%CI 13.1%-20.4%);校正HR 0.61(95%CI 0.55-0.69)。
  • 全因死亡:代谢手术组112例,非手术组1111例;8年累积发生率10.0%(95%CI 7.8%-12.2%) vs 17.8%(95%CI 16.6%-19.0%);绝对风险差7.8%(95%CI 5.1%-10.2%);校正HR 0.59(95%CI 0.48-0.72)。
  • 所有7个预设次要终点均显示代谢手术组有统计学显著差异。

证据类型、等级与局限

  • 证据类型:回顾性观察性队列研究。
  • 作者结论:代谢手术与主要不良心血管事件风险显著降低相关;该观察性研究结果必须在随机临床试验中证实。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于2型糖尿病合并肥胖(BMI≥30)的患者,代谢手术可能与其主要不良心血管事件及全因死亡风险降低相关(观察性研究结果,作者指出需随机临床试验证实)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Although metabolic surgery (defined as procedures that influence metabolism by inducing weight loss and altering gastrointestinal physiology) significantly improves cardiometabolic risk factors, the effect on cardiovascular outcomes has been less well characterized.

OBJECTIVE: To investigate the relationship between metabolic surgery and incident major adverse cardiovascular events (MACE) in patients with type 2 diabetes and obesity.

DESIGN, SETTING, AND PARTICIPANTS: Of 287 438 adult patients with diabetes in the Cleveland Clinic Health System in the United States between 1998 and 2017, 2287 patients underwent metabolic surgery. In this retrospective cohort study, these patients were matched 1:5 to nonsurgical patients with diabetes and obesity (body mass index [BMI] ≥30), resulting in 11 435 control patients, with follow-up through December 2018.

EXPOSURES: Metabolic gastrointestinal surgical procedures vs usual care for type 2 diabetes and obesity.

MAIN OUTCOMES AND MEASURES: The primary outcome was the incidence of extended MACE (composite of 6 outcomes), defined as first occurrence of all-cause mortality, coronary artery events, cerebrovascular events, heart failure, nephropathy, and atrial fibrillation. Secondary end points included 3-component MACE (myocardial infarction, ischemic stroke, and mortality) and the 6 individual components of the primary end point.

RESULTS: Among the 13 722 study participants, the distribution of baseline covariates was balanced between the surgical group and the nonsurgical group, including female sex (65.5% vs 64.2%), median age (52.5 vs 54.8 years), BMI (45.1 vs 42.6), and glycated hemoglobin level (7.1% vs 7.1%). The overall median follow-up duration was 3.9 years (interquartile range, 1.9-6.1 years). At the end of the study period, 385 patients in the surgical group and 3243 patients in the nonsurgical group experienced a primary end point (cumulative incidence at 8-years, 30.8% [95% CI, 27.6%-34.0%] in the surgical group and 47.7% [95% CI, 46.1%-49.2%] in the nonsurgical group [P < .001]; absolute 8-year risk difference [ARD], 16.9% [95% CI, 13.1%-20.4%]; adjusted hazard ratio [HR], 0.61 [95% CI, 0.55-0.69]). All 7 prespecified secondary outcomes showed statistically significant differences in favor of metabolic surgery, including mortality. All-cause mortality occurred in 112 patients in the metabolic surgery group and 1111 patients in the nonsurgical group (cumulative incidence at 8 years, 10.0% [95% CI, 7.8%-12.2%] and 17.8% [95% CI, 16.6%-19.0%]; ARD, 7.8% [95% CI, 5.1%-10.2%]; adjusted HR, 0.59 [95% CI, 0.48-0.72]).

CONCLUSIONS AND RELEVANCE: Among patients with type 2 diabetes and obesity, metabolic surgery, compared with nonsurgical management, was associated with a significantly lower risk of incident MACE. The findings from this observational study must be confirmed in randomized clinical trials.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03955952.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Aminian A, Zajichek A, Arterburn DE, et al. Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity. JAMA. 2019. PMID: 31475297. doi:10.1001/jama.2019.14231

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。